Beyond Mesothelioma, Multiple Sclerosis Could Help Atara’s Stock Soar Exponentially
On Tuesday, Canaccord Genuity reiterated its rating on Atara Biotherapeutics and raised its wildly bullish target price even higher.
Headquartered in Thousand Oaks, CA Fiscal year ends December NASDAQ: ATRA atarabio.com
Atara Biotherapeutics is a T-cell immunotherapy company that develops off-the-shelf allogeneic cell therapies for difficult-to-treat cancers and autoimmune conditions, delivered to patients from inventory. Its T-cell platform targets Epstein-Barr virus (EBV), the root cause of certain diseases, and does not require T-cell receptor or HLA gene editing. The company's lead product is tabelecleucel (tab-cel, marketed as EBVALLO), an allogeneic EBV-specific T-cell therapy. Atara states it was the first company in the world to receive regulatory approval of an allogeneic T-cell immunotherapy. Tab-cel is under FDA review for EBV+ post-transplant lymphoproliferative disease (PTLD) via a BLA resubmission held by partner Pierre Fabre, with a PDUFA target date of March 31, 2027. Atara earns commercialization revenue under its global partnership with Pierre Fabre. It is eligible for a $31 million milestone on U.S. approval, significant double-digit tiered royalties on net sales, and sales-based milestones. Following extensive cost reductions in 2025 and 2026, the company operates with a minimal expense base and a cash runway into mid-2027. Updated
On Tuesday, Canaccord Genuity reiterated its rating on Atara Biotherapeutics and raised its wildly bullish target price even higher.
Atara Biotherapeutics finds itself caught between a rock and a hard place after Friday's drug study news concerning its treatment for multiple sclerosis.
Atara Biotherapeutics is a T-cell immunotherapy company that develops off-the-shelf allogeneic cell therapies for difficult-to-treat cancers and autoimmune conditions, delivered to patients from inventory.
The Wall Street consensus 12-month price target for ATRA is $13.67.